M. Eriksson-Lepkowska

Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

T. Andersson, U. Eriksson, E. Bredberg, 2003, Clinical pharmacokinetics.

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

M. Wolzt, M. Levi, J. Weitz, 2004, Thrombosis and Haemostasis.

No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

U. Eriksson, L. Frison, G. Fager, 2003, Clinical pharmacokinetics.

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r‐hirudin in a human ex vivo model of arterial thrombosis

J. Badimón, J. Osende, U. Eriksson, 2003, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

U. Eriksson, L. Frison, G. Fager, 2003, European Journal of Clinical Pharmacology.

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.

O. Samuelsson, P. Attman, U. Eriksson, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food.

M. Alpsten, B. Abrahamsson, B. Bake, 1998, Journal of controlled release : official journal of the Controlled Release Society.